Citations

Showing 10 of 107964 citations.

VEGF Exerts an Angiogenesis-Independent Function in Cancer Cells to Promote Their Malignant Progression
Cao, Ying , Guangqi, E, Wang, Enfeng , Pal, Krishnendu , Dutta, Shamit K., Bar‐Sagi, Dafna , Mukhopadhyay, Debabrata , Pal, Krishnendu

Mayo Clinic

Cancer Research | June 13, 2012 | Volume: 72 | Issue: 16 | Pages: 3912-3918

10.1158/0008-5472.can-11-4058 | PMID 22693250 Get It

Abstract VEGF/vascular permeability factor (VEGF/VPF or VEGF-A) is a pivotal driver of cancer angiogenesis that is a central therapeutic target in the treatment of malignancy. However, little work has been devoted to investigating functions of VEGF that are independent of its proangiogenic activity. Here, we report that VEGF produced by tumor cells acts in an autocrine manner to promote cell growth through interaction with the VEGF receptor neuropilin-1 (NRP-1). Reducing VEGF expression by tumor cells induced a differentiated phenotype in vitro and inhibited tumor forming capacity in vivo, independent of effects on angiogenesis. Autocrine activation of tumor cell growth was dependent on signaling through NRP-1, and Ras was determined to be a critical effector signaling molecule downstream of NRP-1. Our findings define a novel function for VEGF in dedifferentiation of tumor cells expanding its role in cancer beyond its known proangiogenic function. Cancer Res; 72(16); 3912–8. ©2012 AACR.
Clinical Outcomes in Patients With Renal Artery Stenosis Treated With Stent Placement With Embolic Protection Compared With Those Treated With Stent Alone
Khosla, Ankaj, Misra, Sanjay , Greene, Eddie L., Pflueger, Axel , Textor, S., Bjarnason, Haraldur , McKusick, Michael A., Misra, Sanjay , Bjarnason, Haraldur

Mayo Clinic

Vascular and Endovascular Surgery | June 12, 2012 | Volume: 46 | Issue: 6 | Pages: 447-454

10.1177/1538574412449911 | PMID 22692467 Get It

Purpose: To compare the clinical outcomes in patients with chronic renal insufficiency (CRI) and renal artery stenosis (RAS) following renal artery (RA) stent placement with and without embolic protection device (EPD) usage. Materials and Methods: Eighteen patients who had RA stent placement with EPD were matched to control patients (RA stent only). Blood pressure, number of hypertensive medications, and estimated glomerular filtration rate (eGFR) at 3 months before the procedure and after 12 months were determined. An increase of ≥ 20% in eGFR at 12 months from baseline was defined as “improvement,” decrease of ≥20% as “deterioration,” and an eGFR change between those values as “stabilization” at 12 months. Results: At 12 months, stage 4 patients treated with EPD had significantly higher eGFR than controls ( P = .01). There was no statistical difference in blood pressure outcomes between the 2 groups. Conclusions: Patients with stage 4 CRI did significantly better with EPD than those treated without it.
There Is a Fungus…Among Us
Mayer, Anita P. , Files, Julia A. , Biria, Nazila

Mayo Clinic

Journal of Women's Health | June 12, 2012 | Volume: 21 | Issue: 7 | Pages: 798-799

10.1089/jwh.2012.3710 | PMID 22691033 Get It

Neurological Manifestation of Colonic Adenocarcinoma
Sio, Terence T., Paredes, Mercedes F. , Uzair, Chaudhary

Mayo Clinic

Rare Tumors | June 12, 2012 | Volume: 4 | Issue: 2 | Pages: 98-100

10.4081/rt.2012.e32 | PMID 22826789 Get It

Paraneoplastic neurologic disorders are extremely rare in cancer patients and are most commonly associated with certain tumors, such as ovarian cancer, small cell lung cancer, and breast cancer. We report here a paraneoplastic neurological syndrome in a 53-year-old man with colonic adenocarcinoma with a solitary liver metastasis. His paraneoplastic syndrome was successfully treated by methylprednisolone and primary oncologic therapies including neoadjuvant chemotherapy and definitive surgery. This is also the first documented case of simultaneous manifestation of a sensory neuropathy and limbic encephalitis with colon cancer.
Statins and Risk Reduction in Hepatocellular Carcinoma: Fact or Fiction?
Singh, Siddharth , Singh, Preet Paul

Mayo Clinic

Journal of Clinical Oncology | June 12, 2012 | Volume: 30 | Issue: 20 | Pages: 2569-2570

10.1200/jco.2012.43.2179 | PMID 22689810 Get It

SAAP-RRBS: streamlined analysis and annotation pipeline for reduced representation bisulfite sequencing
Sun, Zhifu , Baheti, Saurabh , Middha, Sumit , Kanwar, Rahul , Zhang, Yuji , Li, Xing , Beutler, Andreas S. , Klee, Eric W. , Asmann, Yan W. , Thompson, E. Aubrey , Kocher, Jean‐Pierre , Sun, Zhifu

Mayo Clinic

Bioinformatics | June 12, 2012 | Volume: 28 | Issue: 16 | Pages: 2180-2181

10.1093/bioinformatics/bts337 | PMID 22689387 Get It

Abstract Summary: Reduced representation bisulfite sequencing (RRBS) is a cost-effective approach for genome-wide methylation pattern profiling. Analyzing RRBS sequencing data is challenging and specialized alignment/mapping programs are needed. Although such programs have been developed, a comprehensive solution that provides researchers with good quality and analyzable data is still lacking. To address this need, we have developed a Streamlined Analysis and Annotation Pipeline for RRBS data (SAAP-RRBS) that integrates read quality assessment/clean-up, alignment, methylation data extraction, annotation, reporting and visualization. This package facilitates a rapid transition from sequencing reads to a fully annotated CpG methylation report to biological interpretation. Availability and implementation: SAAP-RRBS is freely available to non-commercial users at the web site http://ndc.mayo.edu/mayo/research/biostat/stand-alone-packages.cfm. Contact: baheti.saurabh@mayo.edu or sun.zhifu@mayo.edu Supplementary Information: Supplementary data are available at Bioinformatics online.
Incidence of Infective Endocarditis Caused by Viridans Group Streptococci Before and After Publication of the 2007 American Heart Association's Endocarditis Prevention Guidelines
Tleyjeh, Imad M. , de, Daniel D. Correa, Anavekar, Nandan S., Lahr, Brian D. , Sohail, M. Rizwan , Steckelberg, James M., Wilson, Walter R. , DeSimone, Daniel C. , Baddour, Larry M. , Sohail, M Rizwan , Tleyjeh, Imad M

Mayo Clinic

Circulation | June 12, 2012 | Volume: 126 | Issue: 1 | Pages: 60-64

10.1161/circulationaha.112.095281 | PMID 22689929 Get It

Background— The American Heart Association published updated guidelines for infective endocarditis (IE) prevention in 2007 that markedly restricted the use of antibiotic prophylaxis in certain at-risk patients undergoing dental and other invasive procedures. The incidence of IE caused by viridans group streptococci (VGS) in the United States after publication of the 2007 American Heart Association guidelines has not been reported. Methods and Results— We performed a population-based review of all definite or possible cases of VGS-IE using the Rochester Epidemiology Project of Olmsted County, Minnesota. Patient demographics and microbiological data were collected for all VGS-IE cases diagnosed from January 1, 1999, through December 31, 2010. We also examined the Nationwide Inpatient Sample hospital discharge database to determine the number of VGS-IE cases included between 1999 and 2009. We identified 22 cases with VGS-IE in Olmsted County over the 12-year study period. Rates of incidence (per 100 000 person-years) during time intervals of 1999–2002, 2003–2006, and 2007–2010 were 3.19 (95% confidence interval, 1.20–5.17), 2.48 (95% confidence interval, 0.85–4.10), and 0.77 (95% confidence interval, 0.00–1.64), respectively ( P =0.061 from Poisson regression). The number of hospital discharges with a VGS-IE diagnosis in the Nationwide Inpatient Sample database during 1999–2002, 2003–2006, and 2007–2009 ranged between 15 318 to 15 938, 16 214 to 17 433, and 14 728 to 15 479, respectively. Conclusions— On the basis of data complete through 2010, there has been no perceivable increase in the incidence of VGS-IE in Olmsted County, Minnesota, since the publication of the 2007 American Heart Association endocarditis prevention guidelines.
Improving the Detection of Fungi in Eosinophilic Mucin
Guo, Canting, Ghadersohi, Saied , Kephart, Gail M., Laine, Roger A. , Sherris, David A., Kita, Hirohita, Ponikau, Jens U., Kita, Hirohito , Kita, H

Mayo Clinic

Otolaryngology–Head and Neck Surgery | June 12, 2012 | Volume: 147 | Issue: 5 | Pages: 943-949

10.1177/0194599812451010 | PMID 22687329 Get It

Objective To investigate the improvement in histologic detection of fungi with Gomori methenamine silver (GMS) stain by trypsin predigestion in the mucus of patients with chronic rhinosinusitis (CRS). Study Design Prospective, single group, descriptive analysis. Setting Multi‐institutional. Subjects and Methods Thirty‐four sinus specimens from 12 surgical patients with CRS were stained with hematoxylin and eosin, GMS stain, GMS with trypsin digestion, immunofluorescence stains for chitinase, and anti‐ Alternaria . All patients received skin testing, total IgE serology, and radioallergosorbent tests (RAST) for 23 fungal‐specific IgE antibodies. Results The conventional GMS stain detected fungi in only 9 of 34 (27%) specimens. Predigesting the specimen with trypsin dramatically improved the visualization of fungi (31/34, 91%). The chitinase immunofluorescence visualized fungi in 32 of 34 (94%), and anti‐ Alternaria visualized 33 of 34 specimens (97%). Only 8 of 12 (75%) patients had detectable allergies. Conclusions This report describes a simple modification of the conventional GMS stain that can significantly improve the visualization of fungi on histology and explains the lack of detection in previous studies. These novel, more sensitive histologic methods reveal the presence of fungi within the eosinophilic mucin in allergic and also nonallergic CRS patients, further questioning a crucial role of an IgE‐mediated pathophysiology.
Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice
Vicente‐Dueñas, Carolina , Fontán, Lorena , González‐Herrero, Inés, Romero-Camarero, Isabel , Segura, Víctor , Aznar, M. Ángela , Alonso-Escudero, Esther, Campos‐Sánchez, Elena , Ruiz-Roca, Lucía , Barajas-Diego, Marcos, Sagardoy, Ainara, Martínez‐Ferrandis, José I., Abollo‐Jiménez, Fernando , Bértolo, Cristina , Peñuelas, Iván , García‐Criado, Francisco Javier , Cenador, María Begoña García , Tousseyn, Thomas , Agirre, Xabier , Prósper, Felipe , García-Bragado, F., McPhail, Ellen D. , Lossos, Izidore S. , Du, Ming‐Qing , Flores, Teresa, Hernández‐Rivas, Jesús María , Salar, Antonio , Conde, Eulogio, Siebert, Reiner , Sagaert, Xavier , Cobaleda, César , Sánchez-Garcı́a, Isidro , Martinez‐Climent, José A. , McPhail, Ellen Darcy , González, Marcos , Bellosillo, Beatríz , Salar, Antonio , Martinez-Climent, Jose Angel , Prosper, Felipe

Mayo Clinic

Proceedings of the National Academy of Sciences | June 12, 2012 | Volume: 109 | Issue: 26 | Pages: 10534-10539

10.1073/pnas.1204127109 | PMID 22689981 Get It

Chromosomal translocations involving the MALT1 gene are hallmarks of mucosa-associated lymphoid tissue (MALT) lymphoma. To date, targeting these translocations to mouse B cells has failed to reproduce human disease. Here, we induced MALT1 expression in mouse Sca1 + Lin − hematopoietic stem/progenitor cells, which showed NF-κB activation and early lymphoid priming, being selectively skewed toward B-cell differentiation. These cells accumulated in extranodal tissues and gave rise to clonal tumors recapitulating the principal clinical, biological, and molecular genetic features of MALT lymphoma. Deletion of p53 gene accelerated tumor onset and induced transformation of MALT lymphoma to activated B-cell diffuse large-cell lymphoma (ABC-DLBCL). Treatment of MALT1-induced lymphomas with a specific inhibitor of MALT1 proteolytic activity decreased cell viability, indicating that endogenous Malt1 signaling was required for tumor cell survival. Our study shows that human-like lymphomas can be modeled in mice by targeting MALT1 expression to hematopoietic stem/progenitor cells, demonstrating the oncogenic role of MALT1 in lymphomagenesis. Furthermore, this work establishes a molecular link between MALT lymphoma and ABC-DLBCL, and provides mouse models to test MALT1 inhibitors. Finally, our results suggest that hematopoietic stem/progenitor cells may be involved in the pathogenesis of human mature B-cell lymphomas.
Natriuretic Response to Increased Pressure Is Preserved With COX-2 Inhibitors
Gross, Jennifer M., Dwyer, Jennifer E. , Knox, Franklyn G.

Mayo Clinic

Hypertension | June 12, 2012 | Volume: 34 | Issue: 5 | Pages: 1163-1167

10.1161/01.hyp.34.5.1163 | PMID 10567199 Get It

Abstract —Elevation of renal interstitial hydrostatic pressure (RIHP) by direct renal interstitial volume expansion increases sodium excretion. This natriuretic response is blunted by the nonspecific inhibition of the cyclooxygenase (COX) enzymes. The present study tested the hypothesis that the natriuretic response to increased RIHP during direct renal interstitial volume expansion is dependent on COX-1 but not COX-2. RIHP and fractional excretion of sodium (FE Na ) were measured before and after direct renal interstitial volume expansion in control rats (n=7), rats infused with the COX-1 inhibitor piroxicam (n=6, 1.5 mg/kg), and rats infused with the COX-2 inhibitors NS-398 (n=5, 1.5 mg/kg) and meloxicam (n=6, 0.3 mg/kg). In control animals, direct renal interstitial volume expansion significantly increased RIHP (Δ2.3±0.5 mm Hg, P <0.05) and FE Na (Δ1.1±0.3%, P <0.05). Likewise, in animals infused with NS-398 or meloxicam, direct renal interstitial volume expansion significantly increased RIHP (Δ1.8±0.6 mm Hg, P <0.05, and Δ1.7±0.3 mm Hg, P <0.05) and FE Na (Δ1.5±0.4%, P <0.05, and Δ1.1±0.3%, P <0.05), respectively. In contrast, infusion of piroxicam significantly blunted the natriuretic response to direct renal interstitial volume expansion (ΔFE Na 0.3±0.2%), even though RIHP was increased (Δ1.9±0.6 mm Hg, P <0.05). Infusion of piroxicam but not NS-398 or meloxicam blunted the natriuretic response to increased renal interstitial hydrostatic pressure, suggesting that the natriuretic response to increased blood pressure may be preserved during inhibition of COX-2.